Systemic lupus erythematosus and hormone replacement therapy.

Area of Science:

• Reproductive Endocrinology
• Rheumatology
• Cardiovascular Medicine

Background:

• Hormone replacement therapy (HRT) is a standard treatment for menopausal symptoms and osteoporosis prevention.
• Women with systemic lupus erythematosus (SLE) face higher risks of premature menopause, osteoporosis, and cardiovascular disease.
• HRT use in SLE patients is complicated by potential disease flares and thromboembolic events.

Purpose of the Study:

• To review the indications and contraindications of HRT in postmenopausal women, with a specific focus on patients with SLE.
• To outline safe HRT administration strategies for eligible SLE patients.
• To discuss alternative non-estrogen-based treatments.

Main Methods:

• Literature review of studies on HRT, menopause, osteoporosis, SLE, and cardiovascular risks.
• Analysis of clinical guidelines and expert opinions regarding HRT in autoimmune diseases.
• Evaluation of different HRT formulations and administration routes.

Main Results:

• HRT is contraindicated in SLE patients with active disease, a history of thrombosis, or antiphospholipid (aPL) antibodies.
• Non-oral estrogen administration is preferred to minimize effects on coagulation.
• Progesterone or pregnane derivatives are recommended progestogens.

Conclusions:

• HRT should be cautiously considered in postmenopausal women with SLE, strictly avoiding use in those with active disease or thrombotic risk factors.
• Non-estrogen-based therapies are viable alternatives for managing menopausal symptoms in high-risk SLE patients.
• Careful patient selection and administration route are crucial for minimizing HRT-related risks in SLE.